Medline
MDLN
35.45
-0.10
-0.28%
Medline
US · MDLN
#667 by market cap
Listed 2025
35.45
-0.10
-0.28%
Live - 5344 symbols - heartbeat 100s ago
· 2026-10-08 05:19
Pre-market
35.40
-0.14%
After-hours
35.26
-0.54%
Overnight
35.30
-0.42%
- Market cap
- 31.10B
- P/E (TTM)i
- 67.27
- P/Bi
- 2.69
- EPSi
- 1.43
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on MDLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.16, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +11.47% YoY
Margins
- Gross margin
- 26.44%
- Operating margin
- 7.78%
- Net margin
- 4.08%
Key ratios & quality
- Enterprise valuei
- 41.79B
- Altman Z-Scorei
- 2.16
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 21.45B | 23.23B | 25.51B | 28.43B |
| Gross profit | 5.22B | 5.89B | 6.98B | 7.52B |
| Selling & admin expenses | 3.68B | 3.87B | 4.11B | 4.52B |
| Research & development | -- | -- | -- | -- |
| Operating profit | 861.00M | 1.25B | 2.15B | 2.21B |
| Pretax profit | 10.00M | 264.00M | 1.25B | 1.25B |
| Tax | 35.00M | 30.00M | 46.00M | 91.00M |
| Net profit | -25.00M | 234.00M | 1.20B | 1.16B |
| Basic EPS | 0 | 0 | 1 | 1 |
| Diluted EPS | -0.01 | 0.13 | 0.66 | 1.43 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 6.64B | 6.89B | 7.12B | 7.79B | 7.35B | 7.69B |
| Gross profit | 1.82B | 1.91B | 1.88B | 1.91B | 1.84B | 2.22B |
| Selling & admin expenses | 1.07B | 1.07B | 1.12B | 1.27B | 1.23B | 1.30B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 571.00M | 642.00M | 574.00M | 425.00M | 422.00M | 395.00M |
| Pretax profit | 338.00M | 359.00M | 345.00M | 206.00M | 291.00M | 235.00M |
| Tax | 16.00M | 26.00M | 23.00M | 26.00M | 52.00M | 96.00M |
| Net profit | 322.00M | 333.00M | 322.00M | 180.00M | 239.00M | 139.00M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.18 | 0.42 | 0.18 | -0.01 | 0.16 | 0.07 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | -- | 8.81B | 8.27B | 10.68B |
| Cash & ST investments | -- | 1.56B | 199.00M | 1.94B |
| Inventory | -- | 3.81B | 4.46B | 4.77B |
| Total assets | -- | 36.12B | 35.98B | 38.48B |
| Total current liabilities | -- | 2.13B | 2.44B | 2.49B |
| Short-term debt | -- | 122.00M | 154.00M | 143.00M |
| Long-term debt | -- | 16.44B | 16.42B | 12.48B |
| Total liabilities | -- | 19,145,000,000.00 | 19,454,000,000.00 | 19,198,000,000.00 |
| Total equity | -- | 16.98B | 16.52B | 19.29B |
| Retained earnings | -- | -- | 0 | -7.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 8.95B | 9.56B | 10.68B | 11.18B | 11.74B |
| Cash & ST investments | -- | 580.00M | 952.00M | 1.94B | 2.24B | 2.68B |
| Inventory | -- | 4.66B | 4.75B | 4.77B | 4.81B | 4.67B |
| Total assets | -- | 36.43B | 36.88B | 38.48B | 39.01B | 39.35B |
| Total current liabilities | -- | 2.35B | 2.61B | 2.49B | 2.54B | 2.71B |
| Short-term debt | -- | 145.00M | 149.00M | 143.00M | 142.00M | 92.00M |
| Long-term debt | -- | 16.50B | 16.50B | 12.48B | 12.50B | 12.55B |
| Total liabilities | -- | 19,477,000,000.00 | 19,742,000,000.00 | 19,198,000,000.00 | 19,665,000,000.00 | 20,273,000,000.00 |
| Total equity | -- | 16.95B | 17.14B | 19.29B | 19.35B | 19.08B |
| Retained earnings | -- | -- | -- | -7.00M | 122.00M | 182.00M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | 187.00M | 1.69B | 1.77B | 1.74B |
| Depreciation & amortization | 933.00M | 951.00M | 977.00M | 1.01B |
| Free cash flow | -67.00M | 1.41B | 1.42B | 1.30B |
| Dividends paid | -23.00M | -114.00M | -1.52B | -518.00M |
| Stock buybacks / issuance | 0 | 0 | -20.00M | 5.05B |
| Ending cash balance | 399.00M | 1.59B | 250.00M | 1.94B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 682.00M | 197.00M | 636.00M | 229.00M | 412.00M | 715.00M |
| Depreciation & amortization | 247.00M | 250.00M | 253.00M | 261.00M | 254.00M | 256.00M |
| Free cash flow | 584.00M | 87.00M | 535.00M | 91.00M | 316.00M | 604.00M |
| Dividends paid | -- | -- | -119.00M | -96.00M | -- | -- |
| Stock buybacks / issuance | -9.00M | -6.00M | -18.00M | 5.08B | 0 | 0 |
| Ending cash balance | 840.00M | 584.00M | 955.00M | 1.94B | 2.24B | 2.33B |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | 425.45 | 1,304.35 | 21.33 |
| ROA %i | -- | 0.65 | 3.33 | 3.11 |
| ROIC %i | -- | 6.61 | 12.20 | 9.54 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | 4.11 | 5.34 | 8.27 | 7.25 |
| FCF / sales %i | -- | 6.05 | 5.55 | 4.56 |
| Current ratioi | -- | 4.13 | 3.39 | 4.29 |
| Quick ratioi | -- | 2.12 | 1.40 | 2.20 |
| Debt / assetsi | -- | 45.86 | 46.06 | 32.81 |
| LT debt / equityi | -- | 29,894.55 | 99.35 | 116.27 |
| Interest coveragei | 1.01 | 1.27 | 2.44 | 2.54 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 9.85 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 990.63 | 996.85 | 21.33 | 8.60 | 11.98 |
| ROA %i | -- | 3.48 | 3.43 | 3.11 | 2.48 | 1.85 |
| ROIC %i | -- | 12.38 | 12.34 | 9.54 | 6.79 | 6.00 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | 8.22 | 8.03 | 7.25 | 6.64 | 5.76 |
| FCF / sales %i | -- | 4.20 | 3.80 | 4.56 | 3.53 | 5.16 |
| Current ratioi | -- | 3.81 | 3.66 | 4.29 | 4.41 | 4.33 |
| Quick ratioi | -- | 1.67 | 1.68 | 2.20 | 2.33 | 2.34 |
| Debt / assetsi | -- | 45.70 | 45.14 | 32.81 | 32.39 | 32.12 |
| LT debt / equityi | -- | 12,891.41 | 12,992.91 | 116.27 | 110.85 | 108.43 |
| Interest coveragei | -- | 2.57 | 2.58 | 2.54 | 2.64 | 2.66 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Supply Chain Solutions is the largest reported line at 53.94% of revenue, across 2 reported segments.
- Medline Brand follows at 46.06%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Supply Chain Solutions53.94%
Medline Brand46.06%
Quote time 2026-10-08 05:19:38 · For reference only, not investment advice and not tailored to your situation.